Clinical Fueling, Muscle Defense & The Neurobiology of Habit
Daily execution guidelines for the GLP-1 patient: calculating a protein target, supporting muscle protein synthesis with the Leucine Anchor, and recovering from the stress of chronic dieting.
The Leucine Anchor & The Protein Floor
Weight loss without intentional muscle preservation costs strength you want to keep. In the major GLP-1 trials that scanned body composition, roughly a quarter to two fifths of the weight lost was lean mass, which includes muscle along with water and other tissue. Losing muscle lowers daily calorie burn and strength, so protein and resistance training matter.
The Daily Protein Floor
Protein is a physiological need, not a dietary preference. The Shared Agency Framework uses 1.2g per kg as a starting target, within the 1.0 to 1.5g per kg range many obesity clinicians use:
For a 180-lb patient, that is about 98g of protein daily. In higher-weight bodies, many clinicians calculate from an adjusted or goal weight, so ask yours which to use. If you have kidney disease, your protein target must come from your clinician.
The Leucine Anchor (2.5g–3.0g Trigger)
To overcome anabolic resistance and signal your body to retain muscle tissue during a caloric deficit, aim for the "Leucine Threshold" at most meals. Total daily protein and resistance training matter most; the per-meal threshold is best studied in older adults.
Distribute your protein intake across 3 to 4 daily events containing 2.5g to 3.0g of leucine (about 30g of protein from whey, eggs, chicken or beef; plant proteins usually need closer to 40g).
Because your gastric emptying is delayed, volume capacity is constrained. Always consume Protein First to secure your leucine trigger. Eat Fiber and Vegetables Second to maintain gut motility. Consume Complex Carbohydrates Last if capacity permits. Some patients find it helps to sip rather than gulp fluids with meals. Keep total daily fluids up: vomiting, diarrhea and low intake can cause dehydration, which these medicines' labels warn can harm the kidneys.
The Psychological Shift & The Dopamine Void
Quieting the biological signal does not automatically undo thirty years of psychological conditioning. When GLP-1 medications silence the food noise overnight, patients frequently experience a phenomenon of psychological vertigo. We call it The Dopamine Void: a lived experience, not a diagnosis.
Building The Joy List
When food stops working as a coping tool, some patients feel flat or lose interest in things they used to enjoy. Plan for it with non-food sources of pleasure: tactile crafts, creative expression, movement, and unfiltered community. This is not a reason to wait out depression. If low mood lasts more than two weeks, or you have any thoughts of harming yourself, tell your prescriber now; FDA advises reporting new or worsening depression or mood changes on these medicines.
The HPA Axis & Cortisol
Decades of diet cycling, weight stigma and restriction can keep the stress response switched on, and chronic stress can make planning and self-control harder. The research is still developing. Treating metabolic recovery as nervous-system recovery too, with rest, support and, where needed, a therapist, is a sound approach.
The Food Police Pivot
Navigating intrusive dinner-table interrogations requires quick-draw boundary scripts. You owe no one an explanation of your prescription medication, your body size, or what is on your plate. Master the art of the swift conversational pivot.
The GLP-1 "Slow-Start" Patient & Custom Titration
Social media promotes unrealistic narratives of immediate 15-lb drops in Week 1. In reality, a significant cohort of patients are Slow-Starts. Response varies widely, and patients with insulin resistance, a long history of crash dieting, or PCOS often report slower early loss. A slow start during the first months of dose increases is common and is not by itself a sign the medicine has failed.